Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study. (27th November 2017)

• Record Type: Journal Article
• Authors: Horvei, L. D.; Brækkan, S. K.; Smith, E. N.; Solomon, T.; Hindberg, K.; Frazer, K. A.; Rosendaal, F. R.; Hansen, J.‐B.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 16:Number 1(2018)
• Page Start: 83
• Page End: 89
• Publication Date: 2017-11-27
• Subjects: body height -- cohort -- risk -- SNPs -- venous thromboembolism; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.13892
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials Body height and prothrombotic genotypes are associated with risk of venous thromboembolism (VTE). The joint effect of prothrombotic genotypes and tall stature on VTE risk is scarcely investigated. We investigated the joint effect of prothrombotic genotypes and tall stature on VTE risk. Prothrombotic genotypes did not yield excess risk of VTE in subjects with a tall stature. Summary: Background: Studies have reported synergistic effects of prothrombotic single‐nucleotide polymorphisms (SNPs) and obesity on the risk of venous thromboembolism (VTE). Tall stature is associated with an increased VTE risk, but the joint effect of prothrombotic genotypes and tall stature on the VTE risk is unknown. Aims: To investigate the joint effects of prothrombotic genotypes and tall stature on the VTE risk. Methods: Cases with incident VTE ( n = 676) and a randomly selected age‐weighted subcohort ( n = 1842) were sampled from the Tromsø study (cohort follow‐up: 1994–2012). DNA was genotyped for rs6025 (factor V Leiden), rs1799963 (FII), rs8176719 (ABO blood group), rs2066865 (fibrinogen‐γ), and rs2036914 (FIX). Age‐adjusted and sex‐adjusted hazard ratios (HRs) of VTE were calculated by categories of risk alleles (de Haan 5‐SNP score: 0–1, 2–3, and ≥ 4) and body height (< 40th, 40th–80th and > 80th percentiles). Results: The VTE risk increased by increasing category of body height, and subjects with height ≥ 178 cm had a two‐fold higher VTE risk (HR 2.03; 95% confidence interval [CI] 1.51–2.73) than those with height ≤ 165 cm. The VTE risk also increased across categories of risk alleles. However, the combination of a tall stature and risk alleles, either individual SNPs or risk score, did not result in an excess VTE risk. Subjects with four or more risk alleles and height ≥ 178 cm had a two‐fold (HR 2.08; 95% CI 1.24–3.52) higher VTE risk than subjects ≤ 165 cm with no risk allele or one risk allele. Conclusions: In contrast to obesity, the presence of prothrombotic genotypes did not result in an excess VTE risk in subjects with a tall stature.